Reconsidering "at risk" criteria for breast cancer recurrence in hormone positive patients: Risk stratification is still important in patients with an Oncotype Dx recurrence score ≤ 25!

被引：0
|
作者：
Turner, B. M.
Sanders, M. A. G.
Soukiazian, A.
Soukiazian, N.
Hicks, D. G.
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Univ Louisville, Louisville, KY 40292 USA
[3] Univ Rochester, Rochester, NY USA
[4] Drexel Univ, Coll Med, Grad Sch Biomed & Profess Studies, Philadlphia, PA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P2-08-40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-08-40
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Reconsidering "low-risk" criteria for breast cancer recurrence in hormone positive patients
    Soukiazian, Armen
    Hicks, David G.
    Turner, Bradley M.
    BREAST JOURNAL, 2019, 25 (03): : 545 - 547
  • [2] Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
    Andrew Dodson
    David Okonji
    Laura Assersohn
    Anne Rigg
    Amna Sheri
    Nick Turner
    Ian Smith
    Marina Parton
    Mitch Dowsett
    Breast Cancer Research and Treatment, 2018, 168 : 249 - 258
  • [3] Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
    Dodson, Andrew
    Okonji, David
    Assersohn, Laura
    Rigg, Anne
    Sheri, Amna
    Turner, Nick
    Smith, Ian
    Parton, Marina
    Dowsett, Mitch
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 249 - 258
  • [4] Oncotype Dx score associated to pathological features to better prognosticate the risk of recurrence for breast cancer patients.
    Namuche, Fernando
    Ruiz, Rossana
    Morante, Zaida
    Flores, Claudio J.
    Gomez, Henry Leonidas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Ki67 as an important predictor for oncotype Dx recurrence score risk groups in early breast cancer
    Namuche, F.
    Ruiz, R. E.
    Morante Cruz, Z. D.
    Urrunaga, D.
    Aguilar Cartagena, A.
    Gomez Moreno, H. L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score
    Wilson, Parker C.
    Chagpar, Anees B.
    Cicek, Ali F.
    Bossuyt, Veerle
    Buza, Natalia
    Mougalian, Sarah
    Killelea, Brigid K.
    Patel, Natalie
    Harigopal, Malini
    BREAST JOURNAL, 2018, 24 (06): : 976 - 980
  • [7] The effect of Oncotype DX® Recurrence Score on treatment recommendations for geriatric patients with early stage hormone receptor positive breast cancer
    Loftus, L.
    Acs, G.
    Kiluk, J.
    Laronga, C.
    Lee, M. C.
    Soliman, H.
    Boughey, J. C.
    Acs, P.
    Gordon, L.
    Sokol, G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S33 - S34
  • [8] The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists
    Joh, Jennifer E.
    Esposito, Nicole N.
    Kiluk, John V.
    Laronga, Christine
    Lee, M. Catherine
    Loftus, Loretta
    Soliman, Hatem
    Boughey, Judy C.
    Reynolds, Carol
    Lawton, Thomas J.
    Acs, Peter I.
    Gordan, Lucio
    Acs, Geza
    ONCOLOGIST, 2011, 16 (11): : 1520 - 1526
  • [9] The feasibility of obtaining oncotype DX breast recurrence score® results from metastatic sites of patients with hormone receptor positive metastatic breast cancer
    Gemmill, Julie Anne L.
    Thompson, Patricia
    Batiste, Rebecca
    Vacchi-Suzzi, Caterina
    Preece, Christina
    Cohen, Jules
    Baer, Lea
    Mies, Carolyn
    Turner, Michelle
    Russell, Christy A.
    Stopeck, Alison
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy
    Pece, Salvatore
    Sestak, Ivana
    Montani, Francesca
    Tillhon, Micol
    Maisonneuve, Patrick
    Freddi, Stefano
    Chu, Kim
    Colleoni, Marco
    Veronesi, Paolo
    Disalvatore, Davide
    Viale, Giuseppe
    Buus, Richard
    Cuzick, Jack
    Dowsett, Mitch
    Di Fiore, Pier Paolo
    EUROPEAN JOURNAL OF CANCER, 2022, 164 : 52 - 61
12345